Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

Journal of the American Academy of Dermatology

Volumn 76, Issue 1, 2017, Pages 22-28

  Liu, Lucy Y ^a   Craiglow, Brittany G ^a   Dai, Feng ^b   King, Brett A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

alopecia areata; Janus kinase; tofacitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TOFACITINIB; TRIACYLGLYCEROL; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ALOPECIA AREATA; ALOPECIA TOTALIS; ALOPECIA UNIVERSALIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CONJUNCTIVITIS; DIARRHEA; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLICULITIS; HEADACHE; HEART PALPITATION; HERPES ZOSTER; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NAUSEA; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PARESTHESIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEVERITY OF ALOPECIA TOOL; SIDE EFFECT; SKIN BRUISING; SKIN DISEASE ASSESSMENT; TINNITUS; TONSILLITIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERRUCA VULGARIS; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALOPECIA; ALOPECIA AREATA; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85005917093     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.09.007     Document Type: Article

References (16)

1. 1 Safavi, K.H., Muller, S.A., Suman, V.J., et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70 (1995), 628–633.
2. 2 Delamere, F.M., Sladden, M.M., Dobbins, H.M., et al. Interventions for alopecia areata. Cochrane Database Syst Rev, 2008, CD004413.
3. 3 Xing, L., Dai, Z., Jabbari, A., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20 (2014), 1043–1049.
4. 4 Craiglow, B.G., Tavares, D., King, B.A., Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol 152 (2016), 490–491.
5. 5 Craiglow, B.G., King, B.A., Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134 (2014), 2988–2990.
6. 6 Jabbari, A., Dai, Z., Xing, L., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2 (2015), 351–355.
7. 7 Crispin, M., Ko, J., Craiglow, B.G., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15), 2016, e89776.
8. 8 Olsen, E., Hordinsky, M., McDonald-Hull, S., et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 40 (1999), 242–246.
9. 9 Friedland, R., Tal, R., Lapidoth, M., et al. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology 227 (2013), 37–44.
10. 10 Smith, A., Trueb, R.M., Theiler, M., et al. High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol 32 (2015), 481–487.
11. 11 Otberg, N., Finner, A.M., Shapiro, J., Androgenetic alopecia. Endocrinol Metab Clin North Am 36 (2007), 379–398.
12. 12 Wollenhaupt, J., Silverfield, J., Lee, E.B., et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. J Rheumatol 41 (2014), 837–852.
13. 13 Fleischmann, R., Cutolo, M., Genovese, M.C., et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64 (2012), 617–629.
14. 14 Fleischmann, R., Kremer, J., Cush, J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
15. 15 Liu, L.Y., King, B.A., Craiglow, B.G., Health-related quality of life (HRQoL) among patients with alopecia areata: a systematic review. J Am Acad Dermatol 75:4 (2016), 806–812.
16. 16 Colon, E.A., Popkin, M.K., Callies, A.L., et al. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 32 (1991), 245–251.